Shennon Biotechnologies
Shennon Biotechnologies builds a single-cell functional screening platform that discovers T-cell engager targets for solid tumors.
Founded
2021Shennon Biotechnologies builds a single-cell functional screening platform that discovers T-cell engager targets for solid tumors.
Shennon compresses target identification from weeks or months to within a day by screening functionally activated rare T cells at single-cell resolution in hours. Because selection rests on observed killing rather than binding affinity alone, the platform surfaces targets that affinity-only screens can miss.
Its SERIS module predicts toxicity risk early, addressing the off-tumor danger that limits T-cell engagers in solid tumors. The company operates a 6,000-square-foot San Francisco laboratory with clean-room space near UCSF Mission Bay and draws on a network of about fifteen collaborating institutions.
Source: shennonbio.com
Shennon closed an oversubscribed 13M USD seed round in March 2023 led by DCVC with Foundation Capital, AV8, and angel investors, then added 12M USD in September 2026 to reach 25M USD raised to date. The 2026 financing brought Cyril Konto in as chief executive alongside founder Li Sun, who continues as president and chief technology officer.
The company is headquartered at 2325 3rd Street in San Francisco and runs its discovery work from a Mission Bay-area laboratory. Its platform-first model pairs high-throughput functional screening with a T-cell engager pipeline for solid tumors.
Source: dcvc.com
Shennon Biotechnologies runs an integrated discovery engine that combines its PINTRA, AFFINIS, TCELERATOR, and SERIS modules, trained on more than 10,000 tumor samples and over 11 million single cells. Its TCELERATOR system profiles more than 10 million single-cell interactions in a single experiment, ranking candidate targets by observed killing activity.
The company applies this stack to design next-generation T-cell engagers for solid tumors, pairing functional target discovery with early toxicity prediction. Its disclosed pipeline covers programs in small cell lung cancer, ovarian cancer, and hepatocellular carcinoma, with a first development candidate expected to advance toward the clinic.
Source: